HK inno.N Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on HK inno.N's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How HK inno.N makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 839,627 | 41,491 | 244,235 | 18,716 |
| 30 Jun 22 | 830,095 | 34,807 | 237,535 | 18,716 |
| 31 Mar 22 | 763,160 | 20,425 | 231,541 | 18,716 |
| 31 Dec 21 | 769,786 | 21,345 | 224,559 | 18,716 |
| 30 Sep 21 | 743,845 | 28,391 | 219,165 | 17,682 |
| 30 Jun 21 | 706,482 | 32,016 | 218,706 | 17,682 |
| 31 Mar 21 | 652,477 | 33,123 | 199,365 | 17,682 |
| 31 Dec 20 | 598,447 | 27,897 | 193,913 | 17,682 |
| 30 Sep 20 | 559,669 | 20,597 | 222,217 | 4,525 |
| 30 Jun 20 | 550,292 | 13,822 | 217,265 | 4,525 |
| 31 Mar 20 | 546,465 | 14,105 | 207,120 | 7,843 |
| 31 Dec 19 | 539,908 | 13,217 | 188,696 | 15,836 |
| 30 Sep 19 | 526,288 | 28,683 | 165,240 | 27,823 |
| 30 Jun 19 | 508,364 | 22,210 | 169,566 | 27,823 |
| 31 Mar 19 | 499,108 | 35,832 | 174,472 | 24,506 |
| 31 Dec 18 | 490,700 | 47,743 | 187,085 | 16,513 |
Quality Earnings: Insufficient data to determine if A195940 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A195940's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A195940's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A195940's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if A195940's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: A195940 has a negative Return on Equity (0%), as it is currently unprofitable.